Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma
This study is for children with malignant melanoma and high risk features (at high risk of
melanoma returning or spreading to other parts of the body) or who have recurrent disease.
The study has two treatment groups based on the stage of the disease. Patients with stage
IIC, IIIA or IIIB melanoma whose tumors have been removed by surgery will be treated in
study group A. These patients will receive 4 weeks of high dose interferon alpha-2b
followed by 48 weeks of peginterferon. Patients with stage IIIC or IV melanoma, stage III
melanoma that could not be removed by surgery and those with recurrent disease will be
treated in study group B. These patients will receive peginterferon alpha-2b and
Stratum A: Resected Stages IIC, IIIA, and IIIB patients
Induction therapy (weeks 1-4): Subjects will receive recombinant interferon alpha-2b 20
million units/m2 per day intravenously over 20-30 minutes on 5 consecutive days per week for
4 weeks. Subjects will receive peginterferon alpha-2b 1 mcg/kg/week subcutaneously for a
total of 48 weeks.
Stratum B: Resected Stage IIIC, unresectable Stage III, Stage IV, and recurrent patients
Stratum B is divided into 2 groups based on the presence (Stratum B1) or absence (Stratum
B2) of measurable disease. Subjects will receive 8 weekly doses of peginterferon alpha-2b
0.5 mcg/kg/dose subcutaneously in combination with temozolomide 75mg/m2/dose by mouth daily
for 6 weeks followed by 2 week break. The duration of each treatment course will be 8 weeks.
Strata B2 (no measurable disease) will proceed with 7 courses as outlined.
Surgery interventions -Associated with both Strata A and B Surgery description: All subjects
with initial presentation of melanoma (T1-4) will be treated with primary wide local
excision with a minimum of 1cm margin (if anatomically feasible) surrounding the primary
lesion or biopsy scar. For lesions with Breslow's thickness of > 1mm or
sentinel lymph node(s) positive for disease, will undergo complete lymph node dissection of
the involved nodal basin.
Additional objectives include:
- To assess the safety of temozolomide administered in combination with peginterferon
α-2b to pediatric patients with resected AJCC Stage IIIC, unresectable Stage III,
metastatic, or recurrent cutaneous melanoma (Stratum B).
- To study the feasibility and safety of administering peginterferon α-2b weekly for 48
weeks following an initial induction phase with intravenous high dose interferon α-2b
for 4 weeks to pediatric patients with resected thick melanomas (> 4mm) with
ulcerations (AJCC Stage IIC) and resected melanomas with regional lymph node metastases
(AJCC Stage IIIA and IIIB) (Stratum A).
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Tumor response rate after one course of treatment
Fariba Navid, MD
St. Jude Children's Research Hospital
United States: Institutional Review Board
|St. Jude Children's Research Hospital||Memphis, Tennessee 38105-2794|
|Rady Children's Hospital||San Diego, California 92123|
|The Children's Cancer Hospital at UT M.D. Anderson Cancer Center||Houston, Texas 77030|